Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT01372800
Recruiting Observational

Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

NCT01372800 · tracked via the Priya Life Science China tracker
Sponsor
Xijing Hospital
Phase
Observational
Started
2011-05-01
Last updated
2025-02-07

Condition(s) studied

Myocardial InfarctionCerebral Infarction

Study summary

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * available for 5 years of follow-up study Exclusion Criteria: * Death caused other than cardiovascular and cerebralvascular diseases till the study ends * Floating Population * Pregnancy, lactation, or child bearing women * Tumor * Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL * Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L) * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Primary outcome measure(s)

  • Number of Participants with major adverse events — 5 years
    Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.

Trial sites (1)

FacilityCityRegionStatus
Xijing Hospital Xi'an Shaanxi Recruiting

More Xijing Hospital trials in China

Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma. Recruiting
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer Recruiting
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B) Active, not recruiting
Sulodexide in Controlling the Recurrence of Psoriasis Enrolling by invitation
Observational Study of Electrical Impedance Tomography for Non-Invasive Assessment of Cerebral Autoregulation in Neurocritical Patients Recruiting

Other trials for the same condition

Myocardialbridge Bypass Graft Surgery Efficacy Verification Recruiting
Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC） Starting soon
Effects of Myoelectric Biofeedback on Upper Limb Function in Post-stroke Patients Recruiting
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) Recruiting
Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01372800 on ClinicalTrials.gov ↗ ← All trials in China